News
IKT
1.500
-0.66%
-0.010
Inhibikase Therapeutics: Advancing IKT-001 to Revolutionize PAH Treatment and Capture Multi-Billion-Dollar Market
TipRanks · 5d ago
Weekly Report: what happened at IKT last week (1124-1128)?
Weekly Report · 5d ago
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
TipRanks · 11/25 03:52
Major Shareholder Makes a Big Move on Inhibikase Therapeutics Stock!
TipRanks · 11/25 02:08
Sands Capital Life Sciences Pulse Fund II Reports Acquisition of Inhibikase Therapeutics Common Shares
Reuters · 11/24 20:47
Weekly Report: what happened at IKT last week (1117-1121)?
Weekly Report · 11/24 09:12
Inhibikase Therapeutics Announces $93.6 Million Stock Offering
TipRanks · 11/21 21:48
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/21 12:05
Inhibikase Shares Climb After Revised Drug Timeline, Public Offering
Dow Jones · 11/21 11:53
Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 11/21 09:41
Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share
Seeking Alpha · 11/21 08:09
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
TipRanks · 11/21 04:00
*Inhibikase Therapeutics Announces Pricing of $100M Public Offering of Common Stock, Prefunded Warrants >IKT
Dow Jones · 11/21 02:56
*Inhibikase Therapeutics Offering Is Expected to Close Nov. 24 >IKT
Dow Jones · 11/21 02:56
INHIBIKASE THERAPEUTICS INC - PRICES PUBLIC OFFERING OF 46 MLN SHARES AT $1.45 PER SHARE
Reuters · 11/21 02:54
INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF $100 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS
Reuters · 11/21 02:54
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
TipRanks · 11/20 21:50
Inhibikase Therapeutics announces proposed public offering and pre-funded warrants
Seeking Alpha · 11/20 21:39
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study
TipRanks · 11/20 21:29
Inhibikase announces common stock and warrants offering, no amount given
TipRanks · 11/20 21:15
More
Webull provides a variety of real-time IKT stock news. You can receive the latest news about Inhibikase Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).